Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20310851 | 0.91 | FKBP1A (0.43) | FKBP1AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL4045420 | 0.90 | FKBP1A (0.51) | FKBP1AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL12881530 | 0.89 | SMN1; SMN2 (0.42) | FKBP1AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1207252 | 0.89 | FKBP1A (0.42) | FKBP1AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL12881542 | 0.86 | FKBP1A (0.48) | FKBP1AKDM4EALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL5176485 | 0.85 | FKBP1A (0.47) | FKBP1AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL10034638 | 0.81 | FKBP1A (0.48) | FKBP1AKDM4EALDH1A1MAPTGAA | |
| SCHEMBL2913398 | 0.80 | POLB (0.46) | FKBP1ASMN1; SMN2 | |
| SCHEMBL2913400 | 0.80 | POLB (0.46) | FKBP1ASMN1; SMN2 | |
| SCHEMBL4454199 | 0.79 | FKBP1A (0.49) | FKBP1AKDM4EALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-11 | — | — | US | disclosed |
| WO-2017125534-A1 | NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | FKBP1A 1225/4885KDM4E 1868/4885ALDH1A1 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.